[0006a]

In one aspect, the present disclosure refers to a use of an agent comprising 1-(3-(2-(1-Benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof as an active ingredient, in the manufacture of a medicament for treating tauopathy in a human patient who shows the progress of increase in the amount of p-Tau in the brain, wherein the tauopathy is Alzheimer's disease, Probable Alzheimer's disease, Possible Alzheimer's disease, Preclinical Alzheimer's disease, Prodromal Alzheimer's disease, or mild cognitive impairment.

[0006b]

In another aspect, there is provided a use of an agent comprising 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof as an active ingredient , in the manufacture of a medicament for treating tauopathy in a human patient, wherein the tauopathy is Alzheimer's disease characterized by an excessive increase in the amount of p-Tau, Probable Alzheimer's disease characterized by an excessive increase in the amount of p-Tau, Possible Alzheimer's disease characterized by an excessive increase in the amount of p-Tau, Preclinical Alzheimer's disease characterized by an excessive increase in the amount of p-Tau, Prodromal Alzheimer's disease characterized by an excessive increase in the amount of p-Tau, or mild cognitive impairment characterized by an excessive increase in the amount of p-Tau.

Problem to be Solved by the Invention

[0007]

Drugs which suppress progress of AD by inhibiting neurodegeneration need to be developed early. An object of the present invention is to provide a drug and a method which suppress progress of tauopathy such as AD.

Means for Solving Problem

CLAIMS

[Claim 1] Use of an agent comprising 1-(3-(2-(1-Benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof as an active ingredient, in the manufacture of a medicament for treating tauopathy in a human patient who shows the progress of increase in the amount of p-Tau in the brain, wherein the tauopathy is Alzheimer's disease, Probable Alzheimer's disease, Possible Alzheimer's disease, Preclinical Alzheimer's disease, Prodromal Alzheimer's disease, or mild cognitive impairment.

[Claim 2] Use of an agent comprising 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof as an active ingredient , in the manufacture of a medicament for treating tauopathy in a human patient, wherein the tauopathy is Alzheimer's disease characterized by an excessive increase in the amount of p-Tau, Probable Alzheimer's disease characterized by an excessive increase in the amount of p-Tau, Possible Alzheimer's disease characterized by an excessive increase in the amount of p-Tau, Preclinical Alzheimer's disease characterized by an excessive increase in the amount of p-Tau, Prodromal Alzheimer's disease characterized by an excessive increase in the amount of p-Tau, or mild cognitive impairment characterized by an excessive increase in the amount of p-Tau.

[Claim 3] The use according to Claim 1 or 2, wherein the medicament has an effect of reducing the amount of phosphorylated Tau protein.

[Claim 4] The use according to Claim 3, wherein the amount of phosphorylated Tau protein is an amount of phosphorylated Tau protein in CSF.

[Claim 5] The use according to any one of Claims 1 to 4, wherein the medicament has an effect of reducing the amount of amyloid β protein in the brain.

[Claim 6] The use according to any one of Claims 1 to 5, wherein the medicament has an effect of increasing the amount of amyloid β protein in cerebrospinal fluid.

[Claim 7] The use according to any one of Claims 1 to 6, wherein the medicament is to be orally administered in a dose of 100 mg to 400 mg in terms of 1-(3-(2-(1-Benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol once a day.

[Claim 8] The use according to any one of Claims 1 to 7, wherein the medicament is to be orally administered in a dose of 160 mg or 320 mg in terms of 1-(3-(2-(1-Benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol once a day.

[Claim 9] The use according to any one of Claims 1 to 8, wherein the tauopathy is Alzheimer's disease or mild cognitive impairment.

[Claim 10] The use to any one of Claims 1 to 9, wherein the tauopathy is Alzheimer's disease.

[Claim 11] The use according to any one of Claims 1 to 9, wherein the tauopathy is mild cognitive impairment.

[Claim 12] The use according to Claim 11, wherein the mild cognitive impairment is mild cognitive impairment due to Alzheimer’s disease (MCI due to AD).

[Claim 13] The use according to any one of Claims 1 to 12, wherein 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof is to be administered to the patient, and wherein acetylcholinesterase inhibitors are to be administered to the patient for prevention and treatment prior to administration of the 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof.